TABLE 1.
General characteristics of the studies included in systematic review and meta-analysis.
| Author_ year | Country | Setting | Perspective | Target population | Time horizon | Discount rate for costs (%) | References year | Intervention | Comparator | Remarks |
|---|---|---|---|---|---|---|---|---|---|---|
| Van De Laar et al. (2020) | Netherland | Country | Societal | Severe RA | 5 Year | 4.0 | 2019 | csDMARD—Ada Seq | csDMARDs—Bari Seq | Dominated |
| Chen et al. (2019) | Taiwan | Country | Payer | Moderate to severe RA | Lifetime | 3.0 | 2015 | Tofa + MTX | Ada + MTX | Cost effective |
| Claxton et al. (2018) | United States of America | Risk Group | Health System | Moderate to severe RA | Lifetime | 3.0 | 2015 | MTX—Tofa—Ada—Aba—Toci—Ritu | MTX—Eta—Ada—Aba—Toci—Ritu | Cost saving |
| Fatemi et al. (2021) | Iran | Risk Group | Payer | Severe RA | Lifetime | 7.2 | 2019 | Tofa + MTX | Eta-Ada-Ritu | Cost-effective |
| Fournier et al. (2019) * | United States | Country | Health System | Moderate to severe RA | 10 Year | 3.0 | 2018 | Sari—Tofa—csDMARD | Ada—Tofa—csDMARD | Dominant |
| Jansen et al. (2017) | United States | Country | Societal | Moderate to severe RA | Lifetime | 3.0 | 2016 | Eta—Ada—Aba—Toci- Tofa—Ritu—csDMARD | csDMARD | Cost effective |
| Kuwana et al. (2022) | Japan | Country | Health System | Moderate to severe RA | Lifetime | 3.0 | 2020 | Bari + MTX | csDMARD | Cost effective |
| Tian et al. (2020) | China | Country | Health System | Moderate to severe RA | Lifetime | 5.0 | 2018 | Tofa-Tnfi-Toci-PC | Toci + PC | Cost saving |
| Schlueter et al. (2019) | Spain | Country | Health System | Moderate to severe RA | Lifetime | 3.0 | 2018 | Bari | Ada | Cost-effective |
| Lee et al. (2015) | South Korea | Country | Societal | Moderate to severe RA | Lifetime | 5.0 | 2013 | Tofa + MTX—Ada + MTX + Eta + MTX—csDMARD | Ada + MTX + Eta + MTX–csDMARD | Cost effective |
| Muszbek et al. (2019) | United States | Country | Health System | Moderate to severe RA | Lifetime | 3.0 | 2017 | Tofa + MTX | Sari + MTX | Dominant |
| Navarro et al. (2020) | Spain | Country | Health System | Moderate to severe RA | Lifetime | 3.0 | 2018 | Tofa + MTX—Toci + MTX—Aba + MTX- Ritu + MTX | Toci + MTX—Abat + MTX—ritu + MTX—certo + MTX | Dominant |
| Smolen et al. (2016), Li et al. (2021a) | China | Risk Group | Health System | Moderate to severe RA | Lifetime | 3.0 | 2019 | Bari-Ada-Eta-Toci-PC | Ada + MTX | Cost-effective |
| Smolen et al. (2020), Li et al. (2021b) * | China | Risk Group | Health System | Moderate to severe RA | Lifetime | 3.0 | 2019 | TT - Ritu—Tofa | Eta—Aba—Tofa | Cost effective |
| Ha et al. (2021) | South Korea | Risk Group | Societal | Moderate RA | Lifetime | 5.0 | 2019 | Tofa—BDMARDs | csDMARDs | Cost effective |
| Smolen et al. (2016), Tan et al. (2021) | China | Country | Health System | Moderate to severe RA | Lifetime | 3.0 | 2019 | Tofa—Eta—Ritu - Toci | Eta—Ritu—Toci | Dominant |
| Smolen et al. (2020), Tan et al. (2022) | China | Risk Group | Health System | Moderate to severe RA | Lifetime | 3.0 | 2019 | Eta—Tofa—Ritu—Toci | MTX | Not cost-effective |
*
Systematic review, HIC, High-income country; UMIC, Upper middle-income country; LMIC, Lower middle-income country; NR, not, reported; RA, rheumatoid arthritis; MTX, methotrexate; Aba, abatacept; Ritu, Rituximab; Ada, Adalimumab; Toci, Tocilizumab; Goli, Golimumab; Eta, Etanercept; TT, tripple therapy; Tofa, Tofacitinib; Bari, Baricitinib; Certo, Certolizumab; Sari, Sarilumumab; Lefl, Leflunomide; csdmards, conventional synthetic disease-modifying anti rheumatic drugs; Seq, Sequential; PC, Palliative care.